To test this hypothesis, we evaluated a selected panel of SNPs in GSTP1, COMT, and TPMT with cancer outcome, ototoxicity, and peripheral neuropathy in an existing cohort of men with TGCT who have received at least one course of cisplatin-based chemotherapy. The gene discussed is TPMT; the disease is peripheral neuropathy.